Cost-effectiveness analysis of exenatide twice daily (BID) versus insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies
Deng, Jing, Gu, Shuyan, Shao, Hui, Dong, Hengjin, Zou, Dajin, Shi, LizhengLanguage:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696998.2015.1067622
Date:
July, 2015
File:
PDF, 1.22 MB
english, 2015